-
公开(公告)号:EP3386573A1
公开(公告)日:2018-10-17
申请号:EP16820087.1
申请日:2016-12-09
申请人: Amgen Inc.
发明人: YANG, Huaying , YIN, Desheng , TAMTORO, Ferry , GIBSON, Scott R. , KOGLER, Keith P. , FRIEDMAN, Michael , JOHNSTON, Neal , MCCULLOUGH, Adam B.
CPC分类号: A61M5/5086 , A61K38/1793 , A61K38/193 , A61K2039/57 , A61M5/1413 , A61M5/2033 , A61M5/24 , A61M5/2466 , A61M5/3202 , A61M5/3204 , A61M5/3243 , A61M5/326 , A61M5/3286 , A61M5/44 , A61M2005/2086 , A61M2005/3104 , A61M2005/3267 , A61M2205/13 , A61M2205/14 , A61M2205/3368 , A61M2205/3553 , A61M2205/3561 , A61M2205/3584 , A61M2205/36 , A61M2205/3606 , A61M2205/50 , A61M2205/505 , A61M2205/52 , A61M2205/581 , A61M2205/609 , A61M2205/8206 , A61M2205/8212 , C07K14/47 , C07K14/52 , C07K14/535 , C07K14/70578 , C07K16/00 , C07K16/2803 , C07K16/40 , C07K2317/31 , C07K2319/30 , G16H20/17 , G16H40/63 , G16H40/67
摘要: A drug delivery device includes a housing defining a shell, a drug delivery assembly at least partially disposed within the housing, a cap defining an opening and being adapted to at least partially cover an end of the housing, at least one electronic component, a power source which powers the electronic component, and a switch assembly. The drug delivery assembly comprises a guard which engages an inner surface of the housing and is movable between a first, a second, and a third position relative to the housing and are adapted to restrict external contact with a cannula. The switch assembly causes the power source to provide power to the electronic component when the cap is removed from the housing, restrict the power source from providing power when the cap is coupled to the housing and the guard is in the first position, and cause the power source to provide power when the cap is coupled to the housing and the guard is in the third position.
-
92.
公开(公告)号:EP3381942A1
公开(公告)日:2018-10-03
申请号:EP18157842.8
申请日:2013-08-30
申请人: Amgen Inc.
IPC分类号: C07K16/28 , C07K14/535 , A61K48/00 , A61K39/00 , A61K39/395 , A61K35/763
CPC分类号: A61K39/39558 , A61K35/763 , A61K39/3955 , A61K2039/505 , A61K2039/525 , C07K14/535 , C07K16/2818 , C07K2317/21 , C07K2317/76 , C12N2750/14343 , C12N2799/025 , A61K31/00
摘要: The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor.
-
公开(公告)号:EP2619226B1
公开(公告)日:2018-09-12
申请号:EP11763827.0
申请日:2011-09-22
申请人: Amgen Inc.
IPC分类号: C07K16/00 , C07K16/18 , C07K16/28 , A61K39/395
CPC分类号: C07K16/2878 , A61K38/1767 , A61K47/48561 , A61K47/6871 , A61K2039/6056 , C07K16/18 , C07K16/2866 , C07K16/2875 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2319/30
摘要: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
-
公开(公告)号:EP3368101A1
公开(公告)日:2018-09-05
申请号:EP16788129.1
申请日:2016-10-28
申请人: Amgen Inc.
CPC分类号: A61M5/2033 , A61M5/1454 , A61M5/3204 , A61M5/326 , A61M2005/14256 , A61M2005/14506 , A61M2005/206 , A61M2005/31518 , A61M2005/3267
摘要: The present invention relates to a single-use auto-injector for injection of a dosage of a drug into a human body, comprising a housing, and a dosing unit arranged in at least part of the housing, the dosing unit comprising, a needle, a drug container comprising the drug, a piston movable in the container, a first mechanical power supply for supplying a first mechanical force for moving the piston to deliver a drug to the human body, an activation mechanism configured to release the first mechanical power of the first mechanical power supply, and a mechanical brake for controlling the movement of the piston, wherein the auto-injector comprises a second mechanical power supply for supplying a second mechanical force, the auto-injector having, a first state in which the needle is protected from needle damage or contamination, a second state in which the needle is ready to penetrate the human body for dosing the drug, a third state in which the needle has penetrated the human body and is ready to dose, and a fourth state in which the needle is shielded to avoid unintended needle sticks, wherein the second mechanical power supply is configured to shift state of the auto-injector from the third state to the fourth state by releasing the second mechanical power.
-
公开(公告)号:EP2445923B1
公开(公告)日:2018-09-05
申请号:EP10747092.4
申请日:2010-06-21
申请人: Amgen, Inc
IPC分类号: C07K1/113
CPC分类号: C07K1/1136 , C07K1/1133 , C07K1/14 , C07K14/00 , C07K16/00 , C07K2319/30
摘要: A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale.
-
公开(公告)号:EP2699261B1
公开(公告)日:2018-07-11
申请号:EP12717002.5
申请日:2012-04-18
申请人: Amgen Inc.
IPC分类号: A61K39/395
CPC分类号: A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K16/22 , C07K2317/76
摘要: The invention is directed to a method for increasing bone mineral density (BMD) in a postmenopausal woman. The method comprises administering to a postmenopausal woman having a lumbar vertebrae T-score of less than or equal to −2 an anti-sclerostin antibody in an amount and for a time effective to increase lumbar vertebrae BMD at least about 9% from pretreatment baseline at twelve months following initial anti-sclerostin antibody administration. The invention also is directed to a method for treating osteoporosis. The method comprising administering to a postmenopausal woman with osteoporosis an anti-sclerostin antibody in an amount of about 70 mg to about 210 mg at once a month, optionally for about three to about 18 months. Alternatively, the method comprises administering an anti-sclerostin antibody in an amount of about 140 mg to about 210 mg every three months, optionally about six to about 18 months.
-
公开(公告)号:EP3330292A1
公开(公告)日:2018-06-06
申请号:EP17198988.2
申请日:2008-08-19
申请人: Amgen, Inc
发明人: BRASEL, Kenneth, Allan , FOSTER, Stephen , CERRETTI, Douglas, Pat , SUN, Jilin , SMOTHERS, James, F. , MEHLIN, Christopher
IPC分类号: C07K16/28 , A61K39/395 , A61P35/00 , C07K14/715
CPC分类号: C07K16/2866 , A61K2039/505 , C07K14/7153 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要: Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
-
公开(公告)号:EP3300500A1
公开(公告)日:2018-04-04
申请号:EP16730076.3
申请日:2016-05-18
申请人: Amgen Inc.
发明人: CHEN, Ning , CHEN, Xiaoqi , CHEN, Yinhong , CHENG, Alan C. , CONNORS, Richard V. , DEIGNAN, Jeffrey , DRANSFIELD, Paul John , DU, Xiaohui , FU, Zice , HEATH, Julie Anne , HORNE, Daniel B. , HOUZE, Jonathan , KALLER, Matthew R. , KHAKOO, Aarif Yusuf , KOPECKY, David John , LAI, Su-Jen , MA, Zhihua , MCGEE, Lawrence R. , MEDINA, Julio C. , MIHALIC, Jeffrey T. , NISHIMURA, Nobuko , OLSON, Steven H. , PATTAROPONG, Vatee , SWAMINATH, Gayathri , WANG, Xiaodong , YANG, Kevin , YEH, Wen-Chen , DEBENEDETTO, Mikkel V. , FARRELL, Robert P. , HEDLEY, Simon J. , JUDD, Ted C. , KAYSER, Frank
IPC分类号: C07D401/14 , C07D401/04 , C07D413/04 , A61K31/4196 , A61K31/4439 , A61P9/00
CPC分类号: C07D401/14 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/513 , A61K31/695 , A61K45/06 , C07B57/00 , C07B59/002 , C07B2200/05 , C07B2200/07 , C07C311/13 , C07D211/54 , C07D213/61 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D239/34 , C07D241/12 , C07D241/18 , C07D241/24 , C07D249/08 , C07D295/16 , C07D401/04 , C07D401/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F7/08
摘要: where the definitions of the variables are provided herein.
-
公开(公告)号:EP3195163A4
公开(公告)日:2018-02-28
申请号:EP15824123
申请日:2015-07-21
申请人: AMGEN INC , CONNECTMESMART GMBH
发明人: ALBRECHT SABINE , BAUSS MARKUS
CPC分类号: G06F19/3468 , A61J2200/30 , A61M5/20 , G06F17/30247 , G06F17/30477 , G06F19/321 , G06F19/322 , G06F19/3418 , G16H10/60 , G16H20/10
摘要: Methods and systems for determining that a medical delivery device has been activated may be provided. According to certain aspects, a user captures a first image to determine if a medical delivery device is ready to be activated. The first image is transmitted to a health care provider which verifies that the medical delivery device should be activated. If the medical delivery device is to be activated, an electronic device instructs the user to activate the medical delivery device. Subsequently, the user transmits details about the activation of the medical delivery device to the health care provider to update a medical record.
-
公开(公告)号:EP2681242B1
公开(公告)日:2018-01-24
申请号:EP12708472.1
申请日:2012-02-29
申请人: Amgen Inc.
CPC分类号: C07K16/22 , A61K2039/505 , C07K16/18 , C07K2317/31 , C07K2317/64 , C07K2317/76
摘要: The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.
-
-
-
-
-
-
-
-
-